Exhibit 99.1 Press Release CENCORA REPORTS FISCAL 2024 FOURTH QUARTER AND YEAR END RESULTS Revenue of $79.1 Billion for the Fourth Quarter, a 14.7 Percent Year-Over-Year Increase Fourth Quarter GAAP Diluted EPS of $0.02 and Adjusted Diluted EPS of $3.34 Revenue of $294.0 Billion for Fiscal Year 2024, a 12.1 Percent Year-Over-Year Increase Fiscal Year 2024 GAAP Diluted EPS of $7.53 and Adjusted Diluted EPS of $13.76 Company increases its quarterly dividend by 8 percent CONSHOHOCKEN, PA, November 6, 2024 - Ce ...

Cencora (COR) is slated to report fiscal fourth-quarter 2024 results on Nov. 06, before market open.In the last reported quarter, the company delivered a positive earnings surprise of 5.03%. COR’s earnings beat estimates in all the trailing four quarters, delivering an average surprise of 6.59%.Stay up-to-date with all quarterly releases: See Zacks Earnings Calendar.Q4 EstimatesThe Zacks Consensus Estimate for revenues is pegged at $77.68 billion, up 12.7% compared with the prior-year quarter. The consensus ...

Analysts on Wall Street project that Cencora (COR) will announce quarterly earnings of $3.21 per share in its forthcoming report, representing an increase of 12.2% year over year. Revenues are projected to reach $77.68 billion, increasing 12.7% from the same quarter last year.The consensus EPS estimate for the quarter has been revised 0.2% lower over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this time ...

Wall Street expects a year-over-year increase in earnings on higher revenues when Cencora (COR) reports results for the quarter ended September 2024. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates. The earnings report, which is expected to be released on November 6, 2024, might help the stock move higher if these key numbers are better than exp ...

Cencora, Inc. (COR) witnessed strong momentum in the year-to-date period. Shares of the company have rallied 14.7% compared with 2.8% growth of the industry. The S&P 500 Composite has risen 22.5% during the same time frame. With healthy fundamentals and strong growth opportunities, this Zacks Rank #3 (Hold) company appears to be a solid wealth creator for its investors at the moment. Chesterbrook, PA-based Cencora is one of the world's largest pharmaceutical services companies, which focuses on providing dr ...

Cencora (COR) shares soared 3.7% in the last trading session to close at $233.12. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 6.8% loss over the past four weeks. Cencora recorded a strong price rise driven by investors' optimism surrounding the company's upcoming earnings release, scheduled on Nov. 6, 2024. The Zacks Consensus Estimate for the fiscal fourth quarter suggests a revenue growth of 12.7% and earnings growth of 12. ...

Have you been searching for a stock that might be well-positioned to maintain its earnings-beat streak in its upcoming report? It is worth considering Cencora (COR) , which belongs to the Zacks Medical Services industry. This prescription drug distributor has an established record of topping earnings estimates, especially when looking at the previous two reports. The company boasts an average surprise for the past two quarters of 4.57%. For the most recent quarter, Cencora was expected to post earnings of $ ...

Cencora, Inc. (COR) is well-poised for growth on the back of robust U.S. Healthcare Solutions business and product launches. However, intense competition is a concern. Shares of this Zacks Rank #3 (Hold) company have risen 10.3% year to date compared with the industry's 7.4% growth. The S&P 500 Index has risen 17.7% in the same time frame. Cencora is one of the world's largest pharmaceutical service companies, focused on providing drug distribution and related services to reduce healthcare costs and improve ...

It has been about a month since the last earnings report for Cencora (COR) . Shares have lost about 2.8% in that time frame, underperforming the S&P 500. Will the recent negative trend continue leading up to its next earnings release, or is Cencora due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts. Cencora Q3 Earnings Beat Estimates,'24 View Raised C ...

Cencora, Inc. (COR) witnessed strong momentum in the year-to-date period. Shares of the company have rallied 16.6% compared with 6% growth of the industry. The S&P 500 Composite has risen 17.5% during the same time frame. With healthy fundamentals and strong growth opportunities, this Zacks Rank #3 (Hold) company appears to be a solid wealth creator for its investors at the moment. Chesterbrook, PA-based Cencora is one of the world's largest pharmaceutical services companies, which focuses on providing drug ...